Kensaku Matsunami

Dr. Kensaku Matsunami

Ghent University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Open access
KMKensaku Matsunami
Kensaku Matsunami
TMTakuya Miyano
Takuya Miyano
HAHiroaki Arai
Hiroaki Arai
HNHiroshi Nakagawa
Hiroshi Nakagawa
MHMasahiko Hirao
Masahiko Hirao
Hirokazu SugiyamaHirokazu Sugiyama
Hirokazu Sugiyama
This work presents a decision support method for the choice between batch and continuous technologies in solid drug product manufacturing based on the economic evaluation. The method consists of four steps: (I) modeling of operating costs, (II) evaluation, (III) sensitivity analysis, and (IV) interpretation, with iterations. For a given design situation, manufacturing processes are modeled and evaluated with consideration for the characteristics of the two technologies. The sensitivity of the input parameters is analyzed; after interpreting all results, the economically preferable technology is suggested. As a case study, the method was applied to a situation where a new product was in the late development stage, and one of the two technologies needs to be chosen. After executing the four steps, the comparison result of the net present cost was obtained as the decision support information.

1 March 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
KMKensaku Matsunami
Kensaku Matsunami
TNTakuya Nagato
Takuya Nagato
KHKoji Hasegawa
Koji Hasegawa
Hirokazu SugiyamaHirokazu Sugiyama
Hirokazu Sugiyama
This paper compares batch and continuous technologies in terms of product quality and process performance in pharmaceutical tablet manufacturing using ethenzamide as the active pharmaceutical ingredient. Batch and continuous processes using wet granulation were investigated by performing experiments on the scale of 5 and up to 100 kg/lot, using the same raw materials. Three technologies were tested and compared: (i) batch technology using fluidized bed granulation, (ii) batch technology using high shear granulation, (iii) continuous technology using high shear granulation. In the full-scale experiment, in all three technologies including continuous technology, the quality of the tablets fulfilled the target values regarding hardness, active pharmaceutical ingredient content, and dissolution. The granules produced by different technologies, however, presented varying attributes regarding granule size distribution, loose bulk density, or scanning electron microscope images. The process performance, more specifically the yield, was slightly better for batch technologies than for the continuous technology, mainly due to losses in the start-up operation. Notably, this study has shown that continuous technology, which is generally believed to not entail scale-up procedures, could in fact, require parameter adjustment for prolonged operation. The results provided suggestions for improvements to implement large-scale continuous technologies in the pharmaceutical industry.

1 April 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
KMKensaku Matsunami
Kensaku Matsunami
TNTakuya Nagato
Takuya Nagato
KHKoji Hasegawa
Koji Hasegawa
Hirokazu SugiyamaHirokazu Sugiyama
Hirokazu Sugiyama

12 February 2020 in BMC Chemical Engineering
Verified
Journal Article
Open access
PDF file
KMKensaku Matsunami
Kensaku Matsunami
FSFabian Sternal
Fabian Sternal
KYKeita Yaginuma
Keita Yaginuma
STShuichi Tanabe
Shuichi Tanabe
HNHiroshi Nakagawa
Hiroshi Nakagawa
Hirokazu SugiyamaHirokazu Sugiyama
Hirokazu Sugiyama
This paper presents a new method for process synthesis and economic assessment for solid drug product manufacturing, considering continuous manufacturing as a prominent process alternative. Of the three phases of drug development, phase II was targeted where the dosage form, formulation, and processing technology are determined. For a comprehensive alternative generation, a superstructure was developed that covered 9452 options for the unit level, which was combined with two options on the formulation strategy. The generated alternative was assessed by a net present value calculation model, which was adapted for dynamic cash flow consideration in the drug lifecycle. The model can incorporate uncertainty in the drug development and manufacturing in the result, and can perform global sensitivity analysis by Monte Carlo simulation. The method was demonstrated in a case study where two different scenarios regarding the price of the active pharmaceutical ingredient and the demand for the product were assumed. The results showed that when the demand and price are both low, the labor-related costs are dominant, and in the opposite case, the material-related costs become relevant. We also introduce the prototype version of the software “SoliDecision,” by which the presented method was implemented for industrial application.

6 December 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MPMichiel Peeters
Michiel Peeters
AJAna Alejandra Barrera Jiménez
Ana Alejandra Barrera Jiménez
KMKensaku Matsunami
Kensaku Matsunami
MGMichael Ghijs
Michael Ghijs
ESEduardo dos Santos Schultz
Eduardo dos Santos Schultz
TBThomas De Beer
Thomas De Beer

16 January 2023 in Computers & Chemical Engineering
Verified
Journal Article
Closed access
KMKensaku Matsunami
Kensaku Matsunami
TMTomohiro Miura
Tomohiro Miura
KYKeita Yaginuma
Keita Yaginuma
STShuichi Tanabe
Shuichi Tanabe
Sara BadrSara Badr
Sara Badr
Hirokazu SugiyamaHirokazu Sugiyama
Hirokazu Sugiyama